Skip to main content
. 2020 Dec 16;2020:6717912. doi: 10.1155/2020/6717912

Figure 4.

Figure 4

Subgroup analyses for overall survival comparing anti-PD-1/PD-L1 drugs to control treatments in NSCLC patients with PD-L1 expression statuses ≥1% (a) and <1% (b). NSCLC: nonsmall cell lung cancer; PD-1: programmed death 1; PD-L1: programmed death-ligand 1.